About the Company/Team

We’re an early-stage startup on a mission to transform how clinical trials are designed and executed. Our flagship AI agent, TrialMind™, helps pharma, biotech, regulators, and academic researchers move from protocol ideas to executable studies faster, smarter, and with stronger data foundations. Clinical trials are getting more complex, costly, and delayed. We believe generative AI can radically simplify protocol design, streamline data capture, and unlock better evidence for patients. We’re currently building the founding team. If you’re excited about AI agents, digital tools in pharma/medtech R&D, and the challenge of turning cutting-edge ideas into products that matter, we’d love to talk.

About the Role

As our Founding CTO, you’ll own the technical vision and execution for ALAR’s agentic AI platform. You’ll design and ship production-grade AI agents, build out the software and data backbone, and grow the first engineering team. This role is a mix of hands-on builder and future leader, perfect for someone with deep experience in LLMs/AI agents who wants to apply their craft to a high-impact problem in healthcare. Healthcare experience is a plus, but not required.

This is an opportunity to join a company at its inception as a true co-founder. You’ll work directly with the founder (an MD with deep pharma and data science experience) on building a high-impact startup applying AI to clinical trial design. Part-time involvement is acceptable at the start – we know many students balance coursework and projects. Knowledge of pharma/medtech is a plus but not required – you’ll learn on the job from the founder’s expertise and network. You’ll get hands-on experience shaping product direction, running experiments, and interacting with real-world customers and investors. This role is about building, not just observing: you’ll influence strategy, technology, and operations from day one. If you’re excited by AI, healthcare, and entrepreneurship, this is a chance to grow into a key leadership role with equity upside.